Loading
NextSource Biotechnology is the Florida specialty pharma that sells lomustine in the United States as Gleostine, the nitrosourea chemotherapy used in brain tumours and Hodgkin lymphoma.
NextSource Biotechnology is a Miami-based specialty pharmaceutical company. It acquired US rights to lomustine (formerly CeeNU) and markets it as Gleostine, a capsule alkylating agent approved for brain tumours after surgery and radiotherapy and for Hodgkin lymphoma after other treatments. The company drew attention for steep price increases on the drug after the acquisition.
An old chemotherapy pill used when glioblastoma comes back, and the control arm most new glioblastoma drugs must beat.